What exactly changed in the March 4, 2026 SGRY analyst rating updates?

On March 4, 2026 Jefferies maintained **Buy** and lowered its PT to **$16.25**. Cantor Fitzgerald reiterated **Overweight**. RBC Capital kept **Outperform** and trimmed its target referencing the 2026 guide.

How should investors interpret a maintained rating with a lower price target for SGRY?

Maintained ratings with lower targets mean analysts still expect outperformance, but see reduced upside. Investors should weigh continued analyst support against nearer-term revenue and margin risks.

Does the Meyka grade affect the SGRY analyst rating outlook?

Meyka AI rates SGRY **B+**, which incorporates analyst consensus and financial metrics. The grade is an input, not advice. Combine it with analyst notes and company guidance for decisions.

Where can I read the analyst notes and earnings call that influenced these SGRY analyst rating moves?

Key analyst notes and the earnings call are summarized on StreetInsider and Seeking Alpha. See the Jefferies note on StreetInsider and the Q4 2025 transcript on Seeking Alpha for full context.

Analyst Ratings

Jefferies Maintains Buy on Surgery Partners (SGRY) March 2026

ByHuzaifa Zahoor March 5, 2026March 5, 2026

Jefferies maintained a Buy rating on Surgery Partners, Inc. (SGRY) on March 4, 2026. The move kept analyst conviction while lowering the price target to $16.25, a change that pressured the stock intraday. The phrase SGRY analyst rating matters because three major firms reiterated positive stances the same day, balancing optimism about the recovery with caution on 2026 guidance. Investors should note the mix of maintained ratings and price target cuts when sizing positions.